In clinical settings, anti-vascular endothelial growth factor (VEGF) drugs (such as ranibizumab and aflibercept) remain the first-line therapy for DR-related complications such as diabetic macular edema (DME). This evidence concerns the gene VEGFA and diabetic macular edema.